Ibandronate sodium is a nitrogen-containing bisphosphonate.
It is indicated for the treatment and prevention of osteoporosis in postmenopausal women at increased risk of fracture and reduction in the risk of vertebral fractures.
It is formulated as film coated tablets and tablets for oral administration and formulated as injection solution for intravenous route of administration.
Mechanism of action:
Ibandronate sodium inhibits farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signaling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. Ibandronate sodium leads to progressive net gains in bone mass and a decreased incidence of fractures through the reduction of elevated bone turnover towards premenopausal levels in postmenopausal women.